Charleston, SC -- (SBWIRE) -- 09/24/2013 -- The Team of advisers at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer. Have a look at: Decision Diagnostics Corp (OTCBB:DECN), Advanced Cell Technology, Inc. (OTCMKTS:ACTC), Nuvilex Inc (OTCMKTS:NVLX), Cellceutix Corp (OTCBB:CTIX)
Decision Diagnostics Corp (OTCBB:DECN) remained a bull for the day as it reported the upward momentum of +11.27% and closed at $0.790 after gaining total volume of 564,383 shares. Its introductory price for the day was $0.72. So far, the company’s stock is up +267.44% in the three months period. In the last 6 months of trade it reported a gain of +229.17%.
Decision Diagnostics Corp. distributes prescription and non-prescription diagnostics, and home testing products in the United States. The company provides bulk prescription drugs on a wholesale basis; and distributes diabetes diagnostics and supplies.
For How Long DECN’s Gloss will Attract Investors? Find out via this report
Advanced Cell Technology, Inc. (OTCMKTS:ACTC) reported the gain of +2.06% and closed at $ 0.0644 with the total traded volume of 3.23 million shares. The stock's opening price was $ 0.06. The company has a total market capitalization of $ 165.13 million.
The 52-week price range of the stock remained $0.05 - $0.10, while during last trade its minimum price was $0.06 and it gained its highest price of $0.06. Company's last 5 days shows an uptrend with an upsurge of +1.90%. Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine.
Will ACTC Continue To Move Higher? Find Out Here
Nuvilex Inc (OTCMKTS:NVLX) ended its day with the gaining stream with the rise of +2.21% and closed at the price of $0.139 after opening at $0.14. Stock traded during its last trading session with the total volume of 1.84 million shares, as compared to its average volume of 3.07 million shares.
During the previous session, the company’s minimum price was $0.14, while it touched its highest price for the day at $0.14. NVLX’s beta value stands at 0.36 points. Nuvilex, Inc, a biotechnology and life technology company, develops and markets products to improve the health, condition, and well-being.
Why Should Investors Buy NVLX After The Recent Gain? Just Go Here and Find Out
Cellceutix Corp (OTCBB:CTIX) reported the drop of -1.05%, to close at $1.89, with the overall traded volume of 235,720 shares.
So far, in the past three months, the stock is up +7.39%. The 52-week range for the stock is $0.75 and $2.47 and during the previous trading session the stock touched its highest price at $1.98. Its introductory price for the day was $1.97. Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat diseases primarily in the areas of cancer and inflammatory disease.
Has CTIX Found The Bottom and Ready To Move Up? Find Out Here
Our team of advisers here at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the CapitalEquityReport.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
Read Full Disclaimer at: http://capitalequityreport.com/about-us/disclaimer/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)